Tags : DECLARE-TIMI 58 Study

AstraZeneca Reports Positive Results of Farxiga in P-III DECLARE-TIMI 58

Vartika Singh March 19, 2019

Shots: The P-III DECLARE-TIMI 58 study involves assessing of Farxiga (dapagliflozin) vs PBO in 17,000 patients with T2D at risk of CV events (MI) across 33 countries in adults The […]readmore

Tags : DECLARE-TIMI 58 Study

AstraZeneca Reports Positive Results of Farxiga in P-III DECLARE-TIMI 58

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : DECLARE-TIMI 58 Study

AstraZeneca Reports Positive Results of Farxiga in P-III DECLARE-TIMI 58

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company